期刊文献+

外周T细胞淋巴瘤患者外周血中髓源性抑制细胞的表达及意义 被引量:4

The expression and significance of MDSCs in peripheral blood in patients with peripheral T cell lymphoma
下载PDF
导出
摘要 目的探索外周T细胞淋巴瘤(PTCL)患者外周血中髓源性抑制细胞(MDSCs)数量与预后的关系。方法收集PTCL患者23例,选取14例同期健康体检者作为正常对照组,采用流式细胞仪检测其外周血MDSCs/单核细胞比例,分析MDSCs数量与PTCL患者预后及临床特征的关系。结果 MDSCs在PTCL患者外周血单核细胞中所占的比例高于正常对照组[(4.59±1.41)%vs(1.36±0.59)%,P<0.01]。PTCL化疗后外周血MDSCs的表达(1.29±2.95)%较化疗前明显降低。结外侵犯部位、骨髓侵犯、临床分期、IPI评分不同的PTCL患者外周血MDSCs的表达差异有统计学意义(P<0.05)。结论 MDSCs在PTCL患者外周血中高表达,提示与肿瘤发生及预后不良有关。 Objective To study the relationship between the number of myeloid-derived suppressor cells (MDSCs) in peripheral blood and prognosis in patients with peripheral T-cell lymphoma (PTCL). Methods Twenty-three patients with PTCL were selected in this study and 14 healthy persons were used as the normal control. The proportion of MDSCs/mononu-clear in peripheral blood was detected by flow cytometry. The correlation between the number of MDSCs and the clinical character and prognosis in patients with PTCL was analyzed. Results The proportion of MDSCs in peripheral blood was sig-nificantly higher in patients with PTCL than that of healthy subjects [(4.59±1.41)%vs (1.36±0.59)%, P〈0.01]. The number of MDSCs in peripheral blood was significantly decreased after chemotherapy compared with that before treatment [( 1.29 ± 2.95)%, P〈0.05)]. There were significant differences in MDSCs expressions in patients between different extranodal involve-ment, bone marrow involvement, clinical stage and IPI score (P〈0.05). Conclusion The higher expression of MDSCs may be related to the progression in patients with PTCL.
作者 李艳丽 卜庆
出处 《天津医药》 CAS 2015年第3期282-284,共3页 Tianjin Medical Journal
基金 广西自然科学基金青年基金项目(2011GXNSFB018092)
关键词 淋巴瘤 T细胞 外周 流式细胞术 髓源性抑制细胞 lymphoma,T-cell,peripheral flow cytometry myeloid-derived suppressor cells
  • 相关文献

参考文献1

二级参考文献14

  • 1Porembka MR, Mitchem JB, Belt BA, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid- derived suppressor cells which promote primary tumor growth [J]. Cancer Immunol Immunother, 2012, 61(9): 1373-85.
  • 2Gabitass RF, Annels NE, Stocken DD, et al. Elevated myeloid- derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13 [J]. Cancer Immunol Immunother, 2011, 60(10): 1419-30.
  • 3Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin- cyclophosphamide chemotherapy[J]. Cancer Immunol Immunother, 2009, 58(1): 49-59.
  • 4Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer[J]. Cancer J, 2010, 16(4): 348-53.
  • 5Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy[J]. Clin Cancer Res, 2007, 13(18 Pt 1): 5243-8.
  • 6Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients[J]. Clin Cancer Res, 2009, 15(6): 2148-57.
  • 7Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells [J]. Adv Exp Med Biol, 2007, 601: 213-23.
  • 8Zhao F, Obermann S, von Wasielewski R, et al. Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma[J]. Immunology, 2009, 128(1): 141-9.
  • 9Ueha S, Shand FH, Matsushima K. Myeloid cell population dynamics in healthy and tumor-bearing mice [J]. Int Immunopharmacol, 2011, 11(7): 783-8.
  • 10Badn W, Bronte V. Myeloid-derived suppressor cells in cancer[M]// Wang R. Innate immune regulation and cancer immunotherapy. New York: Springer, 2012: 217-29.

共引文献4

同被引文献25

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部